These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27039221)

  • 1. Three-Dimensional Quantitative Validation of Breast Magnetic Resonance Imaging Background Parenchymal Enhancement Assessments.
    Ha R; Mema E; Guo X; Mango V; Desperito E; Ha J; Wynn R; Zhao B
    Curr Probl Diagn Radiol; 2016; 45(5):297-303. PubMed ID: 27039221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does breast MRI background parenchymal enhancement indicate metabolic activity? Qualitative and 3D quantitative computer imaging analysis.
    Mema E; Mango VL; Guo X; Karcich J; Yeh R; Wynn RT; Zhao B; Ha RS
    J Magn Reson Imaging; 2018 Mar; 47(3):753-759. PubMed ID: 28646614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative analysis of background parenchymal enhancement in whole breast on MRI: Influence of menstrual cycle and comparison with a qualitative analysis.
    Jung Y; Jeong SK; Kang DK; Moon Y; Kim TH
    Eur J Radiol; 2018 Jun; 103():84-89. PubMed ID: 29803391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fully Automated Convolutional Neural Network Method for Quantification of Breast MRI Fibroglandular Tissue and Background Parenchymal Enhancement.
    Ha R; Chang P; Mema E; Mutasa S; Karcich J; Wynn RT; Liu MZ; Jambawalikar S
    J Digit Imaging; 2019 Feb; 32(1):141-147. PubMed ID: 30076489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population-Based Assessment of the Association Between Magnetic Resonance Imaging Background Parenchymal Enhancement and Future Primary Breast Cancer Risk.
    Arasu VA; Miglioretti DL; Sprague BL; Alsheik NH; Buist DSM; Henderson LM; Herschorn SD; Lee JM; Onega T; Rauscher GH; Wernli KJ; Lehman CD; Kerlikowske K
    J Clin Oncol; 2019 Apr; 37(12):954-963. PubMed ID: 30625040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of background parenchymal enhancement on breast MRI: a systematic review.
    Bignotti B; Signori A; Valdora F; Rossi F; Calabrese M; Durando M; Mariscotto G; Tagliafico A
    Br J Radiol; 2017 Feb; 90(1070):20160542. PubMed ID: 27925480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative Assessment of Breast Parenchymal Uptake on 18F-FDG PET/CT: Correlation with Age, Background Parenchymal Enhancement, and Amount of Fibroglandular Tissue on MRI.
    Leithner D; Baltzer PA; Magometschnigg HF; Wengert GJ; Karanikas G; Helbich TH; Weber M; Wadsak W; Pinker K
    J Nucl Med; 2016 Oct; 57(10):1518-1522. PubMed ID: 27230924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Association of Background Parenchymal Enhancement at Breast MRI with Breast Cancer: A Systematic Review and Meta-Analysis.
    Thompson CM; Mallawaarachchi I; Dwivedi DK; Ayyappan AP; Shokar NK; Lakshmanaswamy R; Dwivedi AK
    Radiology; 2019 Sep; 292(3):552-561. PubMed ID: 31237494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between qualitative and quantitative assessment of background parenchymal enhancement on breast MRI.
    Pujara AC; Mikheev A; Rusinek H; Gao Y; Chhor C; Pysarenko K; Rallapalli H; Walczyk J; Moccaldi M; Babb JS; Melsaether AN
    J Magn Reson Imaging; 2018 Jun; 47(6):1685-1691. PubMed ID: 29140576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Background parenchymal enhancement over exam time in patients with and without breast cancer.
    Melsaether A; Pujara AC; Elias K; Pysarenko K; Gudi A; Dodelzon K; Babb JS; Gao Y; Moy L
    J Magn Reson Imaging; 2017 Jan; 45(1):74-83. PubMed ID: 27285396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Background Parenchymal Enhancement at Contrast-enhanced Spectral Mammography and Breast MR Imaging.
    Sogani J; Morris EA; Kaplan JB; D'Alessio D; Goldman D; Moskowitz CS; Jochelson MS
    Radiology; 2017 Jan; 282(1):63-73. PubMed ID: 27379544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative Measures of Background Parenchymal Enhancement Predict Breast Cancer Risk.
    Niell BL; Abdalah M; Stringfield O; Raghunand N; Ataya D; Gillies R; Balagurunathan Y
    AJR Am J Roentgenol; 2021 Jul; 217(1):64-75. PubMed ID: 32876474
    [No Abstract]   [Full Text] [Related]  

  • 13. Breast MRI background parenchymal enhancement (BPE) correlates with the risk of breast cancer.
    Telegrafo M; Rella L; Stabile Ianora AA; Angelelli G; Moschetta M
    Magn Reson Imaging; 2016 Feb; 34(2):173-6. PubMed ID: 26597834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inter- and intrareader agreement for categorization of background parenchymal enhancement at baseline and after training.
    Melsaether A; McDermott M; Gupta D; Pysarenko K; Shaylor SD; Moy L
    AJR Am J Roentgenol; 2014 Jul; 203(1):209-15. PubMed ID: 24951217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of background parenchymal enhancement on breast cancer detection with magnetic resonance imaging.
    Telegrafo M; Rella L; Stabile Ianora AA; Angelelli G; Moschetta M
    Diagn Interv Imaging; 2016 Mar; 97(3):315-20. PubMed ID: 26970658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amount of fibroglandular tissue FGT and background parenchymal enhancement BPE in relation to breast cancer risk and false positives in a breast MRI screening program : A retrospective cohort study.
    Vreemann S; Dalmis MU; Bult P; Karssemeijer N; Broeders MJM; Gubern-Mérida A; Mann RM
    Eur Radiol; 2019 Sep; 29(9):4678-4690. PubMed ID: 30796568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraindividual Comparison of Different Methods for Automated BPE Assessment at Breast MRI: A Call for Standardization.
    Müller-Franzes G; Khader F; Tayebi Arasteh S; Huck L; Bode M; Han T; Lemainque T; Kather JN; Nebelung S; Kuhl C; Truhn D
    Radiology; 2024 Jul; 312(1):e232304. PubMed ID: 39012249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI Background Parenchymal Enhancement Is Not Associated with Breast Cancer.
    Bennani-Baiti B; Dietzel M; Baltzer PA
    PLoS One; 2016; 11(7):e0158573. PubMed ID: 27379395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Automated rating of background parenchymal enhancement in MRI of extremely dense breasts without compromising the association with breast cancer in the DENSE trial.
    Wang H; H M van der Velden B; Verburg E; Bakker MF; Pijnappel RM; Veldhuis WB; van Gils CH; Gilhuijs KGA
    Eur J Radiol; 2024 Jun; 175():111442. PubMed ID: 38583349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging.
    King V; Goldfarb SB; Brooks JD; Sung JS; Nulsen BF; Jozefara JE; Pike MC; Dickler MN; Morris EA
    Radiology; 2012 Sep; 264(3):670-8. PubMed ID: 22771878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.